Stress management by benzodiazepines in septic shock and critical illness: mechanistic and clinical evidence supporting alternative sedative strategies.
Key claim: Benzodiazepines may accelerate iatrogenic aging in critically ill and septic patients by antagonizing adaptive stress responses (notably autophagy) and favoring cellular senescence, chronic inflammation, and immunosuppression, and avoiding them in favor of alternative sedatives may attenuate post-intensive-care and post-sepsis syndromes.
Abstract
Critical care involves the management of organismal stress by sedation. Benzodiazepines remain widely used for anxiolysis and sedation in critical care, including in septic shock. Yet converging mechanistic, preclinical and clinical evidence suggests that benzodiazepines and the endogenous ligand of benzodiazepine-binding sites, the “endozepine” acyl-CoA binding protein/diazepam binding inhibitor (ACBP/DBI), may impair host immune defenses, exacerbate organ dysfunction and contribute to long-term morbidity after intensive care. A unifying framework is that benzodiazepines may accelerate “iatrogenic aging” by antagonizing adaptive stress responses (notably autophagy) and favoring cellular senescence, chronic inflammation, immunosuppression and neurocognitive perturbations. Here, we synthesize evidence supporting benzodiazepine avoidance in sepsis-heavy intensive care populations. We propose that replacing benzodiazepines with alternative sedative strategies may improve both short-term outcomes and long-term trajectories of post-sepsis disability. We hypothesize that post-intensive-care syndrome (PICS), including -as a specific case- post-sepsis syndrome (PSS), is caused by premature aging of the organism and that PICS/PSS might be attenuated by the avoidance of benzodiazepine administration during and after critical care.
Why this matters
This finding extends mechanistic aging biology into iatrogenic territory: a widely used ICU drug class is argued to hit the same autophagy–senescence–inflammaging axis the vault tracks for endogenous aging, potentially converting acute critical illness into a durable aging acceleration via post-ICU and post-sepsis syndromes. The claim is a review-level synthesis rather than a controlled human comparison of sedative strategies, so it registers as a mechanistic bridge between critical care pharmacology and hallmark biology rather than as outcome evidence.